Marius Pharmaceuticals
About Marius Pharmaceuticals
Marius Pharmaceuticals develops KYZATREX, an oral testosterone undecanoate therapy absorbed primarily via the lymphatic system, designed to treat adult men with hypogonadism, a condition characterized by low testosterone levels. This therapy addresses the significant health impacts of testosterone deficiency, including fatigue, decreased libido, and increased risk of metabolic disorders, by restoring testosterone levels to the normal range in a majority of patients.
<problem> Many adult men experience hypogonadism, a condition characterized by low or absent testosterone levels, which can lead to fatigue, decreased libido, loss of muscle mass, and increased risk of metabolic disorders. Current testosterone replacement therapies often involve inconvenient administration methods such as injections, topical gels, and creams, leading to compliance issues and potential transference risks. </problem> <solution> Marius Pharmaceuticals offers KYZATREX, an FDA-approved oral testosterone undecanoate therapy designed to address testosterone deficiency in adult men. KYZATREX is administered as a twice-daily softgel capsule, providing a convenient and discreet alternative to traditional methods. The oral formulation is absorbed primarily via the lymphatic system, bypassing the liver and reducing the risk of liver toxicity. Clinical trials have demonstrated KYZATREX's effectiveness in restoring testosterone levels to the normal range, improving symptoms such as low libido, fatigue, and overall quality of life. </solution> <features> - Oral testosterone undecanoate formulation for convenient administration - Softgel capsule designed for twice-daily dosing with food - Lymphatic absorption to bypass the liver and minimize liver toxicity - Demonstrated effectiveness in restoring normal testosterone levels in clinical trials - Shown to improve symptoms of low testosterone, including libido, energy, and mood - Available in 100mg, 150mg, and 200mg dosage strengths - Reduces Sex Hormone Binding Globulin (SHBG) and increases free testosterone levels </features> <target_audience> The primary target audience is adult men diagnosed with hypogonadism (low testosterone) due to specific medical conditions, seeking a convenient and effective testosterone replacement therapy. </target_audience> <revenue_model> Marius Pharmaceuticals generates revenue through the sale of KYZATREX as a prescription medication. </revenue_model>
What does Marius Pharmaceuticals do?
Marius Pharmaceuticals develops KYZATREX, an oral testosterone undecanoate therapy absorbed primarily via the lymphatic system, designed to treat adult men with hypogonadism, a condition characterized by low testosterone levels. This therapy addresses the significant health impacts of testosterone deficiency, including fatigue, decreased libido, and increased risk of metabolic disorders, by restoring testosterone levels to the normal range in a majority of patients.
Where is Marius Pharmaceuticals located?
Marius Pharmaceuticals is based in Raleigh, United States.
When was Marius Pharmaceuticals founded?
Marius Pharmaceuticals was founded in 2017.
How much funding has Marius Pharmaceuticals raised?
Marius Pharmaceuticals has raised 6000000.
- Location
- Raleigh, United States
- Founded
- 2017
- Funding
- 6000000
- Employees
- 16 employees